Reprint

Coronary Syndrome: Clinical Treatment, Prevention and Management for Better Outcomes

Edited by
June 2023
202 pages
  • ISBN978-3-0365-7912-2 (Hardback)
  • ISBN978-3-0365-7913-9 (PDF)

This book is a reprint of the Special Issue Coronary Syndrome: Clinical Treatment, Prevention and Management for Better Outcomes that was published in

Medicine & Pharmacology
Public Health & Healthcare
Summary

This reprint focuses on recent advances in the clinical care of patients with acute and chronic coronary syndromes. We must accumulate novel scientific and clinical knowledge in this field to develop seamless treatments and preventive strategies for this patient population. Furthermore, accumulated data have implicated that there are some residual risk factors for coronary syndromes, and the clinical management of cardiovascular/non-cardiovascular complications associated with coronary syndromes is also a critical concern.

We hope that this reprint will facilitate the management of future patients with coronary syndromes; however, further research is still required. It is also our hope that this reprint will promote future research to enable a better understanding of the clinical practice of coronary syndromes.

Format
  • Hardback
License
© 2022 by the authors; CC BY-NC-ND license
Keywords
statin; myocardial infarction; renal function; coronary CT angiography; subtraction; fractional flow reserve; coronary artery disease; Agatston score; uric acid; endothelial function; ischemic heart disease; ischemia with no obstructive coronary artery disease; angioplasty; drug-eluting stents; non-ST-elevation myocardial infarction; multivessel disease; uric acid; acute coronary syndrome; chronic coronary syndrome; xanthine oxidoreductase; coronary artery spasm; gender differences; vasospastic angina; microvascular spasm; microvascular vasodilatory function; high coronary thrombus burden; tissue plasminogen activator; catheter-directed thrombolysis; olmesartan; amlodipine; rosuvastatin; single pill combination; phase III clinical trial; computed tomography; computed tomography perfusion; myocardial perfusion abnormality; aspirin; clopidogrel; prasugrel; P2Y12 inhibitor; bleeding; vasospastic angina; nitrate; vasodilator; acute coronary syndrome; biomarker; mortality; myocardial infarction; risk-score model; n/a; NGAL; contrast-induced acute kidney injury; coronary artery disease; percutaneous coronary intervention